-
Nov 19, 2024 | 
psychiatrist.com | Christoph U. Correll
Christoph Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellHempstead, NYChristoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, and Chair of the Department of Child and Adolescent Psychiatry at Charité University, Berlin, Germany.
-
Nov 19, 2024 | 
psychiatrist.com | Christoph U. Correll
Christoph Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellHempstead, NYChristoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, and Chair of the Department of Child and Adolescent Psychiatry at Charité University, Berlin, Germany.
-
Nov 19, 2024 | 
psychiatrist.com | Christoph U. Correll
Christoph Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellHempstead, NYTo learn more and watch more videos, visit our Emerging Approaches in Schizophrenia collection at https://bit.ly/emerging-approaches.
-
Nov 14, 2024 | 
onlinelibrary.wiley.com | Anders Fink-Jensen |Christoph U. Correll
LETTER TO THE EDITOR Letter to the Editor Concerning “Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis” Anders Fink-Jensen, Anders Fink-Jensen Mental Health Centre Copenhagen, Mental Health Services—Capital Region of Denmark, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorChristoph U.
-
Nov 8, 2024 | 
onlinelibrary.wiley.com | Anders Fink-Jensen |Christoph U. Correll
Patients with mental disorders have a significantly reduced lifespan,1 with overweight/obesity and cardiometabolic-related death being the biggest contributors. Both the underlying mental illness and treatments, especially antipsychotics, contribute to this increased cardiometabolic risk, creating a dilemma between efficacy and desired safety.
-
Oct 28, 2024 | 
hmpgloballearningnetwork.com | Christoph U. Correll
In this video, Christoph Correll, MD, professor of psychiatry and molecular medicine, Zucker School of Medicine at Hofstra/Northwell, New York, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder. Dr Correll describes strategies ranging from adjunctive medications to lifestyle interventions.
-
Oct 16, 2024 | 
hmpgloballearningnetwork.com | Christoph U. Correll
In this video, Christoph Correll, MD, professor of psychiatry and molecular medicine, Zucker School of Medicine at Hofstra/Northwell, New York, provides a thorough pharmacological overview of the traditional and novel treatments available for schizophrenia. To hear more clinical insights from Dr Correll, check out the first interview in this series: Recognizing the Early Indicators of Schizophrenia.
-
Oct 14, 2024 | 
psychiatrictimes.com | Christoph U. Correll
Christoph U. Correll, MD, shares new data on TEV-'749 for adult patients with schizophrenia. This new positive efficacy, safety, tolerability data from phase 3 SOLARIS trial were presented at the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress in Milan.
-
Oct 11, 2024 | 
psychiatrictimes.com | Christoph U. Correll
Christoph U. Correll, MD, shares new data on Uzedy, an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults, that were presented at the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress in Milan. Uzedy was shown to significantly reduce the risk of relapse in adults with schizophrenia when compared with placebo.
-
Oct 8, 2024 | 
hmpgloballearningnetwork.com | Christoph U. Correll
Videos For the best patient outcomes, early intervention in schizophrenia is key. In this video, Christoph Correll, MD, professor of psychiatry and molecular medicine, Zucker School of Medicine at Hofstra/Northwell, New York, reviews some of the key prodromal and accentuated psychotic symptoms may serve as early indicators of schizophrenia.
